Glucocorticosteroid concentrations in feces and hair of captive caribou and reindeer following adrenocorticotropic hormone challenge.

Climate change and industrial development are contributing to synchronous declines in Rangifer populations across the Arctic. Chronic stress has been implicated as a proximate factor associated with decline in free-ranging populations, but its role in Rangifer is unspecified. Analysis of glucocorticosteroid (GC) concentration in feces, and more recently in hair, is a non-invasive method for monitoring stress in wildlife. Adrenocorticotropic hormone (ACTH) released from the pituitary gland stimulates GC release from the adrenals and can be administered to reflect adrenal activation. In this study, we assessed concentrations of GC metabolites in feces and cortisol in hair of Alaskan caribou (Rangifer tarandus granti) and reindeer (R. t. tarandus) following ACTH treatment. We predicted that ACTH challenge would increase concentrations of fecal GCs, but not hair cortisol because steroid deposited into the hair shaft occurs over an extended period of time (months) and is likely insensitive to acute adrenal stimulation. Adult caribou (n=10; mean age, 6.5 years old) exhibited a peak increase in fecal GCs 8h following a 2 IU/kg dose of ACTH compared to pre-injection concentrations. In contrast, sub-adult reindeer (n=10, 0.8 years old) elicited a diminished response to the same dose. Quadrupling the dose (8 IU/kg) prolonged the fecal GC response in female reindeer, but male reindeer were unresponsive. Hair cortisol was unaffected by a single ACTH challenge. Further investigation is required to ascertain whether subspecific differences in adrenal sensitivity are attributed to age or sex differences, or historical selective pressures from semi-domestication and/or sedentary life cycle in reindeer.

Seasonal changes in testicular size and serum LH, prolactin and testosterone concentrations in male polar bears (Ursus maritimus).

Little is known about the reproductive endocrinology of the male polar bear, Ursus maritimus, except that serum testosterone concentrations are high in April and May during the mating season and are low from August to November during the non-mating season. The objective of this study was to describe the relationship between seasonal changes in testicular size and serum concentrations of testosterone, LH and prolactin. Blood samples and testicular measurements were obtained from free-ranging male polar bears in Canada in April (n = 5) and May (n = 15) near Resolute Bay, Northwest Territories and near Churchill, Manitoba in July (n = 15) and October (n = 22). Testis size was greater in May (39.4 +/- 3.5 cm(2)) than in October (27.3 +/- 2.0 cm(2)) (P = 0.002). Serum testosterone concentrations were approximately three-fold higher in April (5.8 +/- 0.8 ng ml(-1)) than in May (1.7 +/- 0.5 ng ml(-1)), July (0.6 +/- 0.2 ng ml(-1)) and October (1.1 +/- 0.2 ng ml(-1)). Similarly, serum LH concentrations were high in April (0.14 +/- 0.04 ng ml(-1)) and low in May (0.09 +/- 0.01 ng ml(-1)), July (0.10 +/- 0.02 ng ml(-1)) and October (0.08 +/- 0.00 ng ml(-1)). Serum prolactin concentrations were high in April (1.9 +/- 0.3 ng ml(-1)), highest in May (2.5 +/- 0.2 ng ml(-1)), lower in July (1.3 +/- 0.1 ng ml(-1)) and lowest in October (0.8 +/- 0.07 ng ml(-1)). The present study demonstrates a positive relationship between testicular size and serum concentrations of LH, prolactin and testosterone in the male polar bear and confirms the previously reported seasonal changes in serum testosterone concentrations. Data from the present study provide important baseline and comparative endocrine information that can be used to aid captive breeding programmes in zoos and to further ecological-behavioural studies of polar bears.

Anesthesia of wood bison with medetomidine-zolazepam/tiletamine and xylazine-zolazepam/tiletamine combinations.

This study was designed to evaluate 2 combinations for immobilization of bison. Seven wood bison received 1.5 mg/kg body weight (BW) of xylazine HCl + 1.5 mg/kg BW of zolazepam HCl and 1.5 mg/kg BW of tiletamine HCl on one occasion. The bison received 60 micrograms/kg BW of medetomidine HCl + 0.6 mg/kg BW of zolazepam HCl and 0.6 mg/kg BW of tiletamine HCL on another occasion. Xylazine was antagonized with 3 mg/kg BW of tolazoline HCl and medetomidine HCl was antagonized with 180 micrograms/kg (BW) of atipamezole HCl. Temporal characteristics of immobilization and physiological effects (acid-base status, thermoregulatory, cardiovascular, and respiratory effects) of the drug combinations were compared. Induction was significantly faster with xylazine HCl-zolazepam HCl/tiletamine HCl. Recovery following antagonist administration was significantly faster with medetomidine HCl-zolazepam HCl/tiletamine HCl. The average drug volumes required were 7.00 mL of xylazine HCl-zolazepam HCl/tiletamine HCL and 2.78 mL of medetomidine HCl-zolazepam HCl/tiletamine HCl. Hypoxemia, hypercarbia, and rumenal tympany were the major adverse effects with both drug combinations.

Anesthesia of polar bears (Ursus maritimus) with zolazepam-tiletamine, medetomidine-ketamine, and medetomidine-zolazepam-tiletamine.

A 1:1 combination (by weight) of zolazepam and tiletamine is the drug of choice for anesthetizing polar bears (Ursus maritimus), but recovery time is prolonged when additional doses are administered. Recoveries may last 24 hr and may threaten the health of the bears. We compared the anesthetic effects of zolazepam-tiletamine (ZT) with those of medetomidine-ketamine (MK) and medetomidine-zolazepam-tiletamine (MZT) in 93 free-ranging polar bears. The MZT combination was administered in smaller dose and volume, resulted in more rapid, safer, and more predictable induction, provided more reliable anesthesia, and was safely reversed with atipamezole. Frequent occurrence of sudden recoveries during anesthesia with MK limited our use of this combination. MK and MZT sometimes caused apnea and bradycardia initially and hyperthermia at increased ambient temperatures. Hypoxemia occurred transiently with all combinations. When anesthesia with ZT and MK exceeded 1 hr, frequent necessary top-up doses caused irregular physiologic function. ZT is recommended for short duration anesthesia (< or = 1 hr), but MZT is better for anesthesia of longer duration and under circumstances where reversibility is desirable.

Cardiopulmonary response of anesthetized polar bears to suspension by net and sling.

Since 1995, at least three polar bears (Ursus maritimus) have died in the area of Churchill (Manitoba, Canada) as a direct result of being suspended in a net during helicopter-assisted translocations. To assess and improve methods of suspending anesthetized polar bears, we conducted a study during November 1997 to determine the cardiopulmonary responses of eight captive polar bears to suspension by net and by sling. Each bear was anesthetized on two occasions in which the sequence of activities followed and the type of data collected was identical, with only the method of suspension differing. Control data obtained from 11 captive polar bears during 1995-96 was included in the statistical analyses of cardiopulmonary data to help clearly differentiate the cardiopulmonary effects of suspension from those of drug metabolism. Suspending polar bears above the ground by net caused acute hypertension (e.g., 17 to 49% increase in mean arterial pressure), possibly as a result of increased venous return due to body compression. Increased arousal (e.g., head, tongue, and limb movement) also occurred consistently during net-suspension and suggested a stress response. Surprisingly, most suspended bears showed little change in blood gas values, but at least one bear became hypoxemic (i.e., PaO2 < 60 mm Hg) with each method of suspension. Because of the potential health risks of hypertension and hypoxemia, we recommend modifying the method by which polar bears are suspended with the goal of reducing body compression.

Comparative physiologic effects of telazol, medetomidine-ketamine, and medetomidine-telazol in captive polar bears (Ursus maritimus).

The cardiopulmonary effects of three drug combinations in polar bears (Ursus maritimus) were studied. In 1995, five adult polar bears received i.m. injections of either 8.2 +/- 1.3 mg/kg of Telazol or a combination of 159 +/- 34 microg/kg of medetomidine with 4 +/- 0.8 mg/kg of ketamine in a crossover design. Significantly higher mean arterial pressure, lower heart rate, and lower partial pressure of arterial oxygen (Pao2) occurred with medetomidine-ketamine. In 1996, six adult polar bears were immobilized with i.m. injections of either 8.2 +/- 2 mg/kg of zolazepam-tiletamine or a combination of 74.8 +/- 11.8 microg/kg of medetomidine plus 2.2 +/- 0.3 mg/kg of zolazepam-tiletamine in a crossover design. Significantly higher mean arterial pressure and lower heart rate, base excess, and Pao2 occurred with medetomidine-zolazepam-tiletamine compared with zolazepam-tiletamine alone. Hypertension, bradycardia, and decreased Pao2 were observed with both medetomidine-ketamine and medetomidine-zolazepam-tiletamine. Both combinations should be well tolerated by healthy bears, but both have the potential to produce adverse effects in animals with cardiopulmonary disease. Zolazepam-tiletamine produced minimal adverse cardiopulmonary effects, consistent with the wide margin of safety of this combination in bears. The analgesic effect of zolazepam-tiletamine was apparently poor on the basis of the marked increases in pulse rate and mean arterial pressure after noxious stimuli.

Reversible immobilization of free-ranging polar bears with medetomidine-zolazepam-tiletamine and atipamezole.

The objective of this study was to determine if the potent alpha 2 agonist, medetomidine, and its specific antagonist, atipamezole, could be effectively used to immobilize polar bears (Ursus maritimus). Specifically, our goal was to develop a drug combination containing medetomidine that addressed some of the problems such as prolonged recovery time, non-reversibility, and poor analgesia that have been identified with the currently preferred drug combination, zolazepamtiletamine (Telazol or Zoletil). During 1995 and 1996, 51 free-ranging polar bears along the western coast of Hudson Bay, Canada, were immobilized with a combination of medetomidine, zolazepam, and tiletamine (MZT). Immobilization with MZT was characterized by a short induction time, low volume, reliable and predictable immobilization and reversibility, adequate analgesia, and relative safety in handling for field personnel. Few adverse physiological effects were observed in any target animals with the exception of a single bear which convulsed and died shortly after it was reversed from anesthesia with atipamezole. We conclude that MZT is an effective drug combination for immobilizing polar bears. However, because of an unexplained mortality, further investigation of the physiological effects of MZT and atipamezole is warranted.

Physiological effects of medetomidine-zolazepam-tiletamine immobilization in black bears.

A combination of medetomidine-zolazepam-tiletamine (MZT) was used to immobilize four black bears (Ursus americanus). The drugs were used at a dose of approximately 52 micrograms/kg of medetomidine, 0.86 mg/kg of zolazepam, and 0.86 mg/kg of tiletamine. Induction occurred in 6.3 +/- 3.3 min (mean +/- SD). The combination produced minimal adverse cardiopulmonary effects. Hypertension occurred in all four bears. Oxygenation and ventilation was good in three of the four bears. One bear demonstrated slight hypoxemia and hypoventilation at 15 min following drug administration. At one 1 hr following drug administration atipamezole was administered at a dose of approximately 240 micrograms/kg. Recovery time was taken as the time from administration of the atipamezole until the time that the bear was sitting in the trap. Recovery occurred in 6.0 +/- 4.1 min. MZT produced rapid, reliable immobilization in black bears with minimal adverse physiological effects. Immobilization, produced by this combination, was readily reversible with atipamezole.